The Effectiveness of Single Shot Intravesical Chemotherapy with Mitomycin-C in Preventing Recurrence of Non-Muscle Invasive Bladder Cancer
Town Teaching Hospital, Peshawar
DOI:
https://doi.org/10.37762/jgmds.2-2.52Keywords:
Mitomycin-C, transurethral resection, bladder cancer, muscle invasive, EfficacyAbstract
OBJECTIVES:
To determine the efficacy of single dose intravesical chemotherapy with Mitomycin-C following transurethral resection of non-muscle invasive bladder cancer
METHODS:
It was a Descriptive case series study conducted in the admitted patients of bladder cancer in the institute of kidney disease, Peshawar within one year duration. Total of 128 patients were enrolled in the study. After TURBT patient were catheterized with 22 FR 3 ways foley’s catheter and urinary bladder irrigation was started with normal saline. Mitomycin 40 mg dissolved in 20 ml of normal saline was instilled once hematuria settles within 24 hours. All the patients were called back after 3 months for check cystoscopy and the findings were recorded so as to detect recurrence of bladder tumor
RESULTS:
In this study, 128 patients with transurethral resection of non-muscle invasive bladder cancer have been observed; male to female ratio was 5:1. The age ranges of patients were from 18 to 75 years. Average age was 51.13 years + 14.33SD. Recurrence was found in 20(15.62%) of cases while the remaining 108(84.38%) were free of recurrence.
CONCLUSION:
Our study confirmed the effectiveness of a single shot immediate Mitomycin-C instillation in patients with non-muscle-invasive bladder tumors.
Downloads
Metrics
References
Madeb R, GolijaninD, Noyes K, Fisher S, StephensonJJ, Long SR et al. Treatment of Non-MuscleInvadingBladderCancer. Do physicians in theUnited States PracticeEvidenceBased Medicine?The use andeconomicimplications of IntravesicalChemotherapy afterTransurethralResection of Bladder Tumors.Cancer. 2009;115:2660–70 DOI: https://doi.org/10.1002/cncr.24311
SiegelR,Ward E,Brawley O, JemalA.Cancerstatistics, 2011: The impact ofeliminatingsocioeconomicand racialdisparities onprematurecancer deaths. CA CancerJClin. 2011;61:212-15 DOI: https://doi.org/10.3322/caac.20121
Ather MH, Aziz S, SulaimanMN. Single instillationof Mitomycin C Reduces1styear recurrence followingtransurethralresectionofnon-muscleinvasive bladdercancer. JAyub MedColl Abbottabad. 2007;19:18-20
Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, et al. GenomicProfilingof MicroRNAsin BladderCancer: miR-129IsAssociated with PoorOutcome and PromotesCell Death In vitro Cancer Res. 2009;69:115-24 DOI: https://doi.org/10.1158/0008-5472.CAN-08-4043
Persad R, Lammb D, Brausi M, Soloway M, PalouJ, Bohle A. et al. Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparisonof Current Guidelines andRecommendations european urology supplements. 2008;7:637–50 DOI: https://doi.org/10.1016/j.eursup.2008.07.007
Jung SJ, Chang HS,Park CH, KimC,KimBH. Effectivenessofan Immediate Mitomycin CInstillationin Patients with SuperficialBladder Cancer Receiving PeriodicMitomycin C Instillation. Korean J Urol.2011;52:323-6 DOI: https://doi.org/10.4111/kju.2011.52.5.323
Jung SJ, ChangHS, ParkCH, Kim C Il,Kim BH. Effectiveness of anImmediate Mitomycin CInstillation in Patients with SuperficialBladder CancerReceiving PeriodicMitomycin C Instillation. Korean J Urol. 2011;52: 323–6 DOI: https://doi.org/10.4111/kju.2011.52.5.323
Kaasinen E, Rintala E, Hellsrom P, Vitanen J, Juusela H, Rajala P. et al. Factors explainingrecurrence in patients undergoing chemoimmunotherapy regimens for frequentlyrecurringsuperficialbladder carcinoma. Eur Urol. 2007;42:167-74 DOI: https://doi.org/10.1016/S0302-2838(02)00260-9
Babjuk M, OosterlinckW, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelineson non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54:303-14 DOI: https://doi.org/10.1016/j.eururo.2008.04.051
Sylvester RJ, vander Meijden AP, Oosterlinck W, Witjes JA, BouffiouxC,DenisL, et al.Predicting recurrence and progressionin individual patientswithstageTaT1bladder cancer usingEORTC risktables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-5 DOI: https://doi.org/10.1016/j.eururo.2005.12.031
Howlader N, Noone AM,Krapcho M. SEERCancer StatisticReview, 1975–2008,” National Cancer Institute, Bethesda,Md, USA, 2011. Available at: http://seer.cancer.gov/csr/1975 2008
Sylvester RJ, Oosterlinck W, van derMeijden AP. A single immediate postoperative instillation ofchemotherapy decreasesthe risk of recurrenceinpatientswith stageTa T1 bladder cancer: ameta-analysis of published results of randomized clinicaltrials. J Urol. 2004;171:2186-90 DOI: https://doi.org/10.1097/01.ju.0000125486.92260.b2
Babjuk M, OosterlinckW, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelineson non-muscle-invasive urothelial carcinoma of thebladder. Eur Urol. 2008;54:303-14 DOI: https://doi.org/10.1016/j.eururo.2008.04.051
KoyaMP, Simon MA,Soloway MS. Complications of intravesical therapy for urothelial cancer of thebladder. J Urol.2006;175(6):2004–10 DOI: https://doi.org/10.1016/S0022-5347(06)00264-3
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Faiza -Ur- Rehman, Dr., Bilal Khattak, Dr., Irfan -Ul- Islam Nasir, Dr., Muhammad Naeem, Dr.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
